Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren's Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
Hiroto TsuboiHirofumi TokoFumika HondaSaori AbeHiroyuki TakahashiMizuki YagishitaShinya HagiwaraAyako OhyamaYuya KondoKazuhisa NakanoYoshiya TanakaToshimasa ShimizuHideki NakamuraAtsushi KawakamiYuichiro FujiedaTatsuya AtsumiYasunori SuzukiMitsuhiro KawanoNaoshi NishinaYuko KanekoTsutomu TakeuchiHitomi KobayashiMasami TakeiMichihiro OgasawaraNaoto TamuraYoshinari TakasakiKazuhiro YokotaYuji AkiyamaToshihide MimuraKosaku MurakamiTsuneyo MimoriShiro OhshimaNaoto AzumaHajime SanoSusumu NishiyamaIsao MatsumotoTakayuki SumidaPublished in: Modern rheumatology (2022)
Abatacept ameliorated both glandular and extraglandular involvements, as well as the systemic disease activities and patient-reported outcomes based on composite measures, in patients with SS associated with RA.